Click for best price
PD1 PDL1 Immunotherapy Market Size, Share 2023
This report aims to provide a comprehensive presentation of the global market for PD-1 and PD-L1 Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1 and PD-L1 Immunotherapy. This report contains market size and forecasts of PD-1 and PD-L1 Immunotherapy in global, including the following market information:
Global PD-1 and PD-L1 Immunotherapy Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global PD-1 and PD-L1 Immunotherapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
PD-1 inhibitor Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of PD-1 and PD-L1 Immunotherapy include AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck, Pfizer, Roche, Novartis, Jiangsu HengRui Medicine and Innovent, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the PD-1 and PD-L1 Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global PD-1 and PD-L1 Immunotherapy Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global PD-1 and PD-L1 Immunotherapy Market Segment Percentages, by Type, 2022 (%)
PD-1 inhibitor
PD-L1 inhibitor
Global PD-1 and PD-L1 Immunotherapy Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global PD-1 and PD-L1 Immunotherapy Market Segment Percentages, by Application, 2022 (%)
Solid Tumors
Blood-related Tumors
Global PD-1 and PD-L1 Immunotherapy Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global PD-1 and PD-L1 Immunotherapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies PD-1 and PD-L1 Immunotherapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies PD-1 and PD-L1 Immunotherapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Bristol-Myers Squibb
F. Hoffmann-La Roche
Merck
Pfizer
Roche
Novartis
Jiangsu HengRui Medicine
Innovent
Eli Lilly
GlaxoSmithKline
Outline of Major Chapters:
Chapter 1: Introduces the definition of PD-1 and PD-L1 Immunotherapy, market overview.
Chapter 2: Global PD-1 and PD-L1 Immunotherapy market size in revenue.
Chapter 3: Detailed analysis of PD-1 and PD-L1 Immunotherapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of PD-1 and PD-L1 Immunotherapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
PD-1 and PD-L1 Immunotherapy Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
64 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 PD-1 and PD-L1 Immunotherapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global PD-1 and PD-L1 Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global PD-1 and PD-L1 Immunotherapy Overall Market Size
2.1 Global PD-1 and PD-L1 Immunotherapy Market Size: 2022 VS 2030
2.2 Global PD-1 and PD-L1 Immunotherapy Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top PD-1 and PD-L1 Immunotherapy Players in Global Market
3.2 Top Global PD-1 and PD-L1 Immunotherapy Companies Ranked by Revenue
3.3 Global PD-1 and PD-L1 Immunotherapy Revenue by Companies
3.4 Top 3 and Top 5 PD-1 and PD-L1 Immunotherapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies PD-1 and PD-L1 Immunotherapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 PD-1 and PD-L1 Immunotherapy Players in Global Market
3.6.1 List of Global Tier 1 PD-1 and PD-L1 Immunotherapy Companies
3.6.2 List of Global Tier 2 and Tier 3 PD-1 and PD-L1 Immunotherapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global PD-1 and PD-L1 Immunotherapy Market Size Markets, 2022 & 2030
4.1.2 PD-1 inhibitor
4.1.3 PD-L1 inhibitor
4.2 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue & Forecasts
4.2.1 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue, 2018-2023
4.2.2 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue, 2024-2030
4.2.3 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global PD-1 and PD-L1 Immunotherapy Market Size, 2022 & 2030
5.1.2 Solid Tumors
5.1.3 Blood-related Tumors
5.2 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue & Forecasts
5.2.1 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue, 2018-2023
5.2.2 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue, 2024-2030
5.2.3 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global PD-1 and PD-L1 Immunotherapy Market Size, 2022 & 2030
6.2 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue & Forecasts
6.2.1 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue, 2018-2023
6.2.2 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue, 2024-2030
6.2.3 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America PD-1 and PD-L1 Immunotherapy Revenue, 2018-2030
6.3.2 US PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.3.3 Canada PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.3.4 Mexico PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe PD-1 and PD-L1 Immunotherapy Revenue, 2018-2030
6.4.2 Germany PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4.3 France PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4.4 U.K. PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4.5 Italy PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4.6 Russia PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4.7 Nordic Countries PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4.8 Benelux PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia PD-1 and PD-L1 Immunotherapy Revenue, 2018-2030
6.5.2 China PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.5.3 Japan PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.5.4 South Korea PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.5.5 Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.5.6 India PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America PD-1 and PD-L1 Immunotherapy Revenue, 2018-2030
6.6.2 Brazil PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.6.3 Argentina PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue, 2018-2030
6.7.2 Turkey PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.7.3 Israel PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.7.4 Saudi Arabia PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.7.5 UAE PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
7 PD-1 and PD-L1 Immunotherapy Companies Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.1.4 AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Company Summary
7.2.2 Bristol-Myers Squibb Business Overview
7.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.2.5 Bristol-Myers Squibb Key News & Latest Developments
7.3 F. Hoffmann-La Roche
7.3.1 F. Hoffmann-La Roche Company Summary
7.3.2 F. Hoffmann-La Roche Business Overview
7.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.3.4 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.3.5 F. Hoffmann-La Roche Key News & Latest Developments
7.4 Merck
7.4.1 Merck Company Summary
7.4.2 Merck Business Overview
7.4.3 Merck PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.4.4 Merck PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.4.5 Merck Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.5.4 Pfizer PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 Roche
7.6.1 Roche Company Summary
7.6.2 Roche Business Overview
7.6.3 Roche PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.6.4 Roche PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.6.5 Roche Key News & Latest Developments
7.7 Novartis
7.7.1 Novartis Company Summary
7.7.2 Novartis Business Overview
7.7.3 Novartis PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.7.4 Novartis PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.7.5 Novartis Key News & Latest Developments
7.8 Jiangsu HengRui Medicine
7.8.1 Jiangsu HengRui Medicine Company Summary
7.8.2 Jiangsu HengRui Medicine Business Overview
7.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.8.4 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.8.5 Jiangsu HengRui Medicine Key News & Latest Developments
7.9 Innovent
7.9.1 Innovent Company Summary
7.9.2 Innovent Business Overview
7.9.3 Innovent PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.9.4 Innovent PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.9.5 Innovent Key News & Latest Developments
7.10 Eli Lilly
7.10.1 Eli Lilly Company Summary
7.10.2 Eli Lilly Business Overview
7.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.10.4 Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.10.5 Eli Lilly Key News & Latest Developments
7.11 GlaxoSmithKline
7.11.1 GlaxoSmithKline Company Summary
7.11.2 GlaxoSmithKline Business Overview
7.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.11.4 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.11.5 GlaxoSmithKline Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. PD-1 and PD-L1 Immunotherapy Market Opportunities & Trends in Global Market
Table 2. PD-1 and PD-L1 Immunotherapy Market Drivers in Global Market
Table 3. PD-1 and PD-L1 Immunotherapy Market Restraints in Global Market
Table 4. Key Players of PD-1 and PD-L1 Immunotherapy in Global Market
Table 5. Top PD-1 and PD-L1 Immunotherapy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global PD-1 and PD-L1 Immunotherapy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies PD-1 and PD-L1 Immunotherapy Product Type
Table 9. List of Global Tier 1 PD-1 and PD-L1 Immunotherapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 PD-1 and PD-L1 Immunotherapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - PD-1 and PD-L1 Immunotherapy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - PD-1 and PD-L1 Immunotherapy Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - PD-1 and PD-L1 Immunotherapy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - PD-1 and PD-L1 Immunotherapy Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 30. AstraZeneca Company Summary
Table 31. AstraZeneca PD-1 and PD-L1 Immunotherapy Product Offerings
Table 32. AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 33. AstraZeneca Key News & Latest Developments
Table 34. Bristol-Myers Squibb Company Summary
Table 35. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product Offerings
Table 36. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 37. Bristol-Myers Squibb Key News & Latest Developments
Table 38. F. Hoffmann-La Roche Company Summary
Table 39. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product Offerings
Table 40. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 41. F. Hoffmann-La Roche Key News & Latest Developments
Table 42. Merck Company Summary
Table 43. Merck PD-1 and PD-L1 Immunotherapy Product Offerings
Table 44. Merck PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 45. Merck Key News & Latest Developments
Table 46. Pfizer Company Summary
Table 47. Pfizer PD-1 and PD-L1 Immunotherapy Product Offerings
Table 48. Pfizer PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 49. Pfizer Key News & Latest Developments
Table 50. Roche Company Summary
Table 51. Roche PD-1 and PD-L1 Immunotherapy Product Offerings
Table 52. Roche PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 53. Roche Key News & Latest Developments
Table 54. Novartis Company Summary
Table 55. Novartis PD-1 and PD-L1 Immunotherapy Product Offerings
Table 56. Novartis PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 57. Novartis Key News & Latest Developments
Table 58. Jiangsu HengRui Medicine Company Summary
Table 59. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product Offerings
Table 60. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 61. Jiangsu HengRui Medicine Key News & Latest Developments
Table 62. Innovent Company Summary
Table 63. Innovent PD-1 and PD-L1 Immunotherapy Product Offerings
Table 64. Innovent PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 65. Innovent Key News & Latest Developments
Table 66. Eli Lilly Company Summary
Table 67. Eli Lilly PD-1 and PD-L1 Immunotherapy Product Offerings
Table 68. Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 69. Eli Lilly Key News & Latest Developments
Table 70. GlaxoSmithKline Company Summary
Table 71. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product Offerings
Table 72. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 73. GlaxoSmithKline Key News & Latest Developments
List of Figures
Figure 1. PD-1 and PD-L1 Immunotherapy Segment by Type in 2022
Figure 2. PD-1 and PD-L1 Immunotherapy Segment by Application in 2022
Figure 3. Global PD-1 and PD-L1 Immunotherapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global PD-1 and PD-L1 Immunotherapy Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global PD-1 and PD-L1 Immunotherapy Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by PD-1 and PD-L1 Immunotherapy Revenue in 2022
Figure 8. By Type - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 9. By Application - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 10. By Type - Global PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 12. By Application - Global PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 14. By Region - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 15. By Country - North America PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 16. US PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 17. Canada PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 20. Germany PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 21. France PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 23. Italy PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 24. Russia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 28. China PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 29. Japan PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 32. India PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 34. Brazil PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 37. Turkey PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 38. Israel PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 40. UAE PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 41. AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Merck PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Pfizer PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Roche PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Novartis PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Innovent PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
